Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight loss ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including new semaglutide ...

(Reuters) - Manufacturers of the 10 prescription drugs subject to price negotiations for the U.S. Medicare program have signed on... By Sruthi Shankar, Siddarth S and Shristi Achar A (Reuters ...